FIG. 3.

Proapoptotic peptide treatment did not produce a CTA at the same dose that results in reduced energy intake and weight loss. A: Preference ratio over 24 h. Subcutaneous administration of 0.15 mol/l LiCl resulted in reduced intake of the flavor paired with LiCl compared with mice treated with equiosmotic NaCl. All data are represented as means ± SEM. Saline, n = 8; LiCl, n = 8; LF-V, n = 6; HF-CP, n = 6; HF-PP, n = 12. *P < 0.05. B: Effect of proapoptotic peptide on energy expenditure during the second week of treatment. O₂ consumption was adjusted for lean mass as determined by nuclear magnetic resonance. LF-V, n = 8; HF-CP, n = 8; HF-PP, n = 8.